Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYU688
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EYU688 is an investigational small molecule antiviral drug developed by Novartis for the treatment of dengue fever. It acts as an inhibitor of the nonstructural protein 4B (NS4B) of the dengue virus, a target involved in viral replication. Preclinical studies have shown that EYU688 is highly effective against all four serotypes of dengue virus, with EC50 values ranging from 8 to 38 nM in Vero cells and significant reduction in viremia in animal models. The drug is currently being evaluated in Phase 2 clinical trials to assess its efficacy, safety, and pharmacokinetics when administered orally to patients with dengue fever[1][2][3][5][7].
02
Targets
NS4B (Hepatitis C virus NS4B)
Beyond the preview
Go deeper on EYU688.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYU688.